BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 24, 2006
 |  BioCentury  |  Strategy

A nAChR-al fit

Athenagen Inc. is seeking to entrench its position in the nicotinic acetylcholine receptor pathway by acquiring Osprey Pharmaceutical Co., which has both a clinical compound and a portfolio of preclinical small molecules that target the pathway in the brain. Athenagen believes the assets will complement its own preclinical pipeline of reformulated products that address nAChR peripherally.

W. Scott Harkonen, president and CEO of Athenagen, said the acquisition "fits hand in glove." Athenagen (South San Francisco, Calif.) is developing reformulated versions of approved...

Read the full 407 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >